Stallergenes Greer acquires Palforzia peanut allergy treatment business from Nestle

Nestlé announced that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies.

The transaction was closed upon signing. This agreement follows Nestlé’s announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

Peanut allergy currently affects approximately 2% of the general population of Western nations and the
prevalence of peanut allergy doubled among children between 2005 and 2015. The difficulty of avoiding
peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for
effective treatment